FP01. The Association of Bevacizumab with a Decreased Risk of Brain Metastases in ECOG-ACRIN E1505 in Completely Resected Stage IB-IIIA NSCLC - Slides

FP01. A Comparative Cost Analysis Study of Robotic and Video-Assisted Lobectomy: Results of Randomized Controlled Trial (Bravo Trial) - Slides

FP01. Prevalence, Treatment Patterns and Long-Term Clinical Outcomes of Patients with EGFR Positive Resected Stage IB-IIIA NSCLC

FP01. Prospective Observational Study of Activities of Daily Livings in Elderly Patients After Lung Cancer Surgery (JCOG1710A)

FP02. Utilization and Refusal of Adjuvant Chemotherapy for Non-Small Cell Lung Cancer: A National Cancer Database Study - Slides

FP02. The Impact of Sex on Non-Small Cell Lung Cancer Survival in Canada

FP02. Factors Associated With Delayed Lung Cancer Diagnosis

FP02. Immunotherapy in Lung Cancer: Analysis of Patients’ Awareness and Perceptions - Slides

FP03. A Phase I Trial of Atezolizumab and Varlilumab in Combination With Radiation in Patients with Metastatic Non-Small Cell Lung Cancer - Slides

FP03. ECOG PS of 0-1 and Very High PD-L1 Expression ≥90% Are Associated With Clinical Benefit From First-Line Chemo-Immunotherapy in Advanced NSCLC - Slides

FP03. Dasatinib Improves the Antitumor Activity of Anti-PD-1 in NSCLC Models by Inhibiting Treg Conversion and Proliferation - Slides

FP04. Nivolumab 480 mg Every 4 Weeks as De Novo Second-line Treatment for Advanced Non-Small Cell Lung Cancer: CheckMate 907

FP04. RATIONALE-307: Updated Biomarker Analysis of Phase 3 Study of Tislelizumab Plus Chemo vs Chemo Alone For 1L Advanced Sq-NSCLC

FP04. Clinical Benefit of First-Line Cemiplimab in Patients with Locally Advanced NSCLC: Subgroup Analysis from EMPOWER-Lung 1

FP04. A Phase Ib/II Study of Imprime PGG and Pembrolizumab in Pretreated Patients With Advanced Stage Non-Small Cell Lung Cancer: BTCRC-LUN15-017

FP05. A Biomarker-Directed, Multi-Center Phase II Study of Molecular Response Adaptive Immuno-Chemotherapy in Lung Cancer

FP05. Multiomic, Plasma-Only ctDNA NGS Assay Developed for Minimal Residual Disease (MRD) Detection in Early-Stage NSCLC - Slides

FP05. Robust Discrimination of Lung Cancer via Microbial DNA Detection and Machine Learning Classification

FP05. A Prospective Observational Study of Osimertinib Using Plasma Concentrations in NSCLC With Acquired EGFR T790M Mutation - Slides

FP06. Unexpected Aggressive Histological Component in Subsolid Lung Adenocarcinoma: Priority for Resection Without Delay - Slides

FP06. The Impact of The COVID-19 Pandemic on New Diagnoses of Lung Cancer: A 3-Year Review of an Irish Cancer Centre - Slides

FP06. COVID-19: Does Thoracic Surgery Increase Mortality Rates during the Pandemic? - Slides

FP07. The MDM2/p53 Axis is a Therapeutic Vulnerability in Malignant Pleural Mesothelioma - Slides

FP07. Next Generation Sequencing Portrays Mutation Profilings of Malignant Pleural and Peritoneal Mesotheliomas - Slides

FP07. Diagnostic Potential of Novel Mesothelioma-Specific MicroRNAs

FP07. Effect of Tumor Treating Fields (TTFields) on DNA Damage and The FA-BRCA DNA Repair Pathway in Mesothelioma

FP07. DREAM3R: Durvalumab With Chemotherapy as First Line Treatment in Advanced Pleural Mesothelioma - A Phase 3 Randomised Trial

FP08. Lung Stereotactic Body Radiation Therapy for Treatment of Oligoprogressive and Oligorecurrent Metastatic Disease: A Multi-Center Analysis

FP08. Artificial Neural Network-Based Tumour Recurrence Prediction in Non-Small Cell Lung Cancer Patients Following Radical Radiotherapy

FP08. Outcomes With Multi-Disciplinary Management of Central Lung Tumors Treated With Percutaneous High-Dose-Rate Brachytherapy

FP08. Tumour Spread Through Air Space (STAS) In Lung Metastases - Slides

FP09. Mobocertinib in Platinum-Pretreated EGFR Exon 20 Insertion+ Metastatic NSCLC Patients With/Without Prior Anti-PD(L)-1 Therapy

FP09. Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes From EXCLAIM Extension Cohort

FP09. Phase II Randomized Trial to Evaluate Prednisone Taper With or Without Nintedanib for the Treatment of Radiation Pneumonitis

FP09. Impact of Brain Metastasis Status on Adverse Events (AEs) Requiring Dose Reduction Among Patients Receiving Lorlatinib

FP10. The Efficacy of Immunotherapy in non-Small Cell Lung Cancer Patients with Uncommon Mutations: a Real World Research from Single Site - Slides

FP11. Sustaining and Accelerating Research in Rare Oncogene-Driven Lung Cancers: Lessons From The 2020 ROS1der Research Roundtable

FP12. PD-L1 Assessment in Cytology is Comparable to Histology in Predicting Treatment Response to Checkpoint Inhibitors in NSCLC

FP12. Pembrolizumab as a Monotherapy or in Combination With Platinum-Based Chemotherapy in NSCLC: Correlation With Blood Biomarkers

FP12. Associations of Urinary Biomarkers of Tobacco Toxicants With Lung Cancer Incidence in Smokers: The Multiethnic Cohort Study

FP12. Obesity is Associated With Greater Overall Survival in Patients With Metastatic NSCLC Receiving First-Line Pembrolizumab

FP12. The Intrinsic Limitation and Clinical Impact of Mutant Allele-Specific Real-Time PCR-Based EGFR Mutation Assay in NSCLC

FP12. Solid Subtype Predicts Early Bone Metastases in Sensitive EGFR-Mutated Lung Adenocarcinoma Patients After Surgery - Slides

FP12. Clinico-demographic Factors, EGFR status and their association with Stage at Diagnosis in Lung Adenocarcinoma Patients

FP12. Lung Adenocarcinomas with ROS1 Rearrangement show Diffuse Strong ROS1 Immunohistochemical Staining

FP13. Assessment of the Fear of COVID-19 and Its Impact on Lung Cancer Screening Participation Among the Korean General Population

FP13. Costal Pleura-attached Noncalcified Nodules Newly Seen on Annual Low-Dose CT Screenings - Slides

FP13. The Impact of the COVID-19 Pandemic on Lung Cancer Screening Programs in the United States

FP13. CHECK Lung Protocol: CT Lung Cancer Screening is Useful to Adjuvant Comorbid Diseases Diagnosis

FP14. A Phase 1b/2 Study of Autologous Dendritic Cell Vaccination in Combination With Atezolizumab in Patients With Small Cell Lung Cancer (SCLC) - Slides

FP14. Small Cell Lung Carcinoma’s Clinical Versatility Is a Manifestation of Its Shape-Shifting Cellular Programs

FP14. Diagnostic Accuracy in Central Pulmonary Carcinoid tumors is Dependent of Biopsy Size - Slides

FP15. Randomized Single-Blind Comparative Study of Midazolam Plus Pethidine Combination and Midazolam During Bronchoscopy

FP16. Development and Characterization of Two Novel Squamous Cell Lung Cancer Mouse Cell Lines - Slides

FP16. Genomic Characterization of Primary versus Metastatic Lung Adenocarcinoma - Slides

FP16. Early Circulating-Tumor DNA EGFR Mutation Clearance in Plasma as a Predictor of Clinical Outcomes in The AURA3 Trial

FP16. A Nationwide Population-Based Mapping of Mutations and Gene Fusions in Lung Cancer Among Never-Smokers

FP16. Computational Omics Biology Model (CBM) Identifies Novel Biomarkers to Inform Combination Platinum Compound Therapy in NSCLC - Slides

P01. LIBRETTO-432: A Placebo-Controlled Phase 3 Study of Adjuvant Selpercatinib in Stage IB-IIIA RET Fusion-Positive NSCLC - Slides

P01. High Risk Factors and Benefit of Adjuvant Chemotherapy in Surgically Resected Stage IB Non–Small Cell Lung Cancer - Slides

P02. CT Integrated Bronchoscopy Manual Spraying Pigment Labeling to Localize of Small Pulmonary Nodules - Slides

P02. Transbronchial Microwave Ablation of Lung Nodules in the Hybrid Operating Room – Mid-Term Follow Up of a Novel Technique - Slides

P02. Robotic Bronchoscopy: Navigating the Change in Lung Nodule Management - Slides

P02. Three Cases of Endoscopic Snare Resection for Tracheal and Main Bronchial Tumors - Slides

P02. Yield of Tumor Samples With A Guide-sheath in Endobronchial Ultrasound Transbronchial Biopsy For Non-small Cell Lung Cancer - Slides

P03. Pathologic Response to Neoadjuvant PD-1 Inhibitors and Chemotherapy in Squamous Non-Small-Cell Lung Cancer - Slides

P03. Osimertinib as Neoadjuvant Therapy for Resectable EGFR Mutant Non-small Cell Lung Cancer: A Real-World Multicenter Retrospective Study - Slides

P04. Presence of Ground Glass Opacity Component is True Determinant of Prognosis in Clinical Stage I Non-Small Cell Lung Cancer - Slides

P04. Efficacy of Multidisciplinary Team-Based Evaluation of Patients With Suspicious Pulmonary Lesions - Slides

P05. Personalized Optimization of TCP Using NTCP Based Constraints for Ultracentral Lung Tumors - Slides

P05. Does Non-Small Cell Lung Cancer Histologic Type Influence Outcomes with Single-Fraction Stereotactic Body Radiotherapy? - Slides

P05. Comparison of Stereotactic Body Radiotherapy and Radiofrequency Ablation for Early-Stage NSCLC: A Systemic Review and Pooled Analysis - Slides

P05. Impact of Lung Stereotactic Body Radiotherapy on Pulmonary Function Test – Experience from Tertiary Cancer Centre in India - Slides

P05. Clinical Application of Anatomical Landmarkers Based 3D Precise Pulmonary Nodule Localization During Thoracoscopic Surgery - Slides

P05. Stereotactic Body Radiotherapy for Early-Stage Non-Small Cell Lung Cancer Without Pretreatment Pathologic Results in a Chinese Population - Slides

P06. Propensity-Matched Analysis Comparing Survival after Thoracoscopic Wedge Resection versus Segmentectomy for cT1N0 Lung Adenocarcinoma - Slides

P06. Incorporating Surgical Collapse in the Pathological Assessment of Resected Adenocarcinoma in situ of the Lung. A Proof of Principle Study. - Slides

P06. Clinical Outcomes and Pathological Characteristics of Resected ALK+ Lung Adenocarcinoma: A Single Center Retrospective Analysis - Slides

P06. Risk Factors for Recurrence According to Site in Resected Stage I Non-Small Cell Lung Cancer - Slides

P06. Clinical Implications of Tumour Spread Through Air Spaces (STAS) In Lung Adenocarcinoma Patients Treated With Surgery - Slides

P06. Learning Curve in Robotic-Assisted Thoracoscopic Pulmonary Resection: Experience of a Brazilian Surgeon - Slides

P06. Treatment Outcome of Second Primary Lung Cancer - Slides

P06. Lobectomy for Lung Cancer, What Is the Brazilian reality? Brazilian Society of Thoracic Surgeons Analysis - Slides

P06. Low-Cost Video-Assisted Thoracic Surgery (VATS) Lobectomy Versus Regular VATS Lobectomy: A Propensity-Matched Study - Slides

P07. Usage Patterns of TKIs in EGFR Mutant NSCLC: Let's Get REAL - Slides

P07. Real World data of Advanced Non-Small Cell Lung Cancer Patients EGFR Mutated from a Peruvian Cohort - Slides

P07. Lung Cancer Under 50 Years Old – What Reality Taught Us - Slides

P07. Primary Lung Cancers in Patients With Head and Neck Cancer: Experience of a French Institution - Slides

P08. Building Personalized Follow-Up Care Through AI by Bringing the Lung Cancer Patient, Data Scientist and Oncologist Together - Slides

P08. Lorlatinib in First Line Treatment of Patients With ALK-Positive NSCLC: A Network Meta-Analysis - Slides

P08. Cost‑Effectiveness of Pembrolizumab With or Without Chemotherapy for Stage IV Non‑Squamous NSCLC with High PD‑L1 in Switzerland - Slides

P08. Comparative Clinical Outcomes Between EGFR Exon20ins and Wildtype NSCLC Treated with Immune Checkpoint Inhibitors - Slides

P08. Impact of Personal Characteristics on the Effectiveness of Immunotherapy Treatment in Late-Stage NSCLC: A Systematic Review - Slides

P09. A Clinical Evaluation Algorithm to Define Clinical Utility of Lung Nodule Diagnosis in a Multi-Collaborator Setting Using Real World Data - Slides

P09. Validation of a Real-World Mortality Endpoint for Advanced Non-Small Cell Lung Cancer Patients in China - Slides

P09. Evaluating Mutational Differences Between Hispanics and Asians in NSCLC - Slides

P09. Variation of Treatment Recommendations for Stage III Non-Small-Cell Lung Cancer by Stage and Actionable Mutations - Slides

P09. Patient Behaviors and Attitudes Towards Lung Cancer Medication Adherence - Slides

P09. Integration of Smoking Cessation Services in Mobile Mammography and Mobile COVID Screening to Reach Rural Populations - Slides

P10. Real World Data of Clinical Trial Eligibility and Outcome Analysis in Patients With Metastatic NSCLC - Slides

P10. Improved Survival of Elderly Patients with NSCLC Treated in the Immunotherapy Era: A Historical Cohort Study - Slides

P10. Pembrolizumab With or Without Chemotherapy for Advanced Lung Cancer: A Real-World Analysis of Key Prognostic Factors - Slides

P10. Immunotherapy-Treated Non-Small Cell Lung Cancer Patients With Sensitizing Gene Alterations: A Real World Survival Analysis - Slides

P10. Adherence to Treatment Recommendations From Multidisciplinary Tumor Boards

P10. Affiliation to the Labour Market in Denmark for Patients Under 60 Years of Age After Diagnosis and Treatment for ALK-Positive NSCLC - Slides

P10. Real-World US Treatment Patterns and Clinical Outcomes in Advanced NSCLC After Prior Platinum Chemotherapy and Immunotherapy - Slides

P10. Comparing Lung Cancer in Never Smokers and Ever Smokers in Asian or Asian American Patients Treated at a Tertiary Urban Public Hospital in New York - Slides

P10. Efficacy and Toxicity of EGFR-TKI in Frail NSCLC with EGFR Mutation: A Retrospective Analysis in a Single Institution - Slides

P10. A Thorough Look at the Clinical Characteristics and Disease Burden of Lung Cancer Patients in Chinese County Area - Slides

P10. Real World Outcomes for Non Small Cell Lung Cancer Treated With Checkpoint Inhibitors in Lebanon, A Multicenter Observational Study - Slides

P10. ctDNA and Real-World Response (rwR) in Patients With Lung Cancer From A Prospective Real-World Clinico-Genomic (PCG) Study - Slides

P11. Phase I Trial of in Situ Vaccination With Autologous CCL21-Modified Dendritic Cells (CCL21-DC) Combined With Pembrolizumab for Advanced NSCLC - Slides

P11. Targeting the Tumor Neovasculature in Lung Cancer: A Phase I Study of AMG 160 in Subjects With Non-Small Cell Lung Cancer - Slides

P11. SHR-1316 in Combination With Fluzoparib in Relapsed Small-Cell Lung Cancer: An Open-Label, Multicenter, Two-Stage, Phase Ⅰb Trial - Slides

P12. A Novel 89Zr-α-PD-1 Immuno-PET-CT May Improve Pseudoprogression Detection in a Lung Cancer Murine Model Receiving Immunotherapy - Slides

P12. Systemic Anticancer Therapy Upregulate Plasma Levels of Damage-Associated Molecular Patterns in Patients With Advanced Lung Cancer - Slides

P12. The Time of Anti-PD-1 Infusion Improves Survival Outcomes by Fasting Conditions Simulation in Non-Small Cell Lung Cancer - Slides

P12. Radiation Mediates IDO1 Dynamic Changes in KRAS Mutation Lung Cancer Cell Lines - Slides

P12. Computational Omics Biology Model (CBM) Identifies PD-L1 Immunotherapy Response Criteria Based on Genomic Signature of NSCLC - Slides

P12. Radiation Mediated Down-Regulation of Indoleamine 2,3-dioxygenase 1 (IDO1) Expression in Lung Cancer Cells is Associated with iNOS-NO Pathway - Slides

P13. Use of Antibiotics Is Associated With an Increase in Immunotherapy Related Adverse Effects in Patients With Non-Small Cell Lung Cancer - Slides

P14. Phase 3 Study of First-Line Pembrolizumab ± Vibostolimab (anti-TIGIT) in Patients With PD-L1‒Positive Metastatic NSCLC - Slides

P14. Phase III Trial of Pembrolizumab‑Chemotherapy Versus Pembrolizumab in First‑Line of Advanced NSCLC with PD‑L1 ≥50%: PERSEE - Slides

P14. Vibostolimab Plus Pembrolizumab With/Without Docetaxel vs Docetaxel in NSCLC After Platinum Chemotherapy and Immunotherapy - Slides

P14. A Phase 2 Multicenter Study of Iovance Autologous Tumor Infiltrating Lymphocytes (TIL, LN-145) Cell Therapy in Patients With Metastatic NSCLC - Slides

P14. Phase 2, Study of Iovance Autologous Tumor Infiltrating Lymphocytes (Lifileucel, LN-144, LN-145, LN-145-S1) In Patients With Solid Tumors - Slides

P14. Toripalimab in Combination With Bevacizumab and Platinum-Based Chemotherapy in Patients with Untreated Advanced PSC: A Phase II Study - Slides

P14. PERLA: Randomized Phase II Trial of Dostarlimab + Chemotherapy (CT) vs Pembrolizumab + CT in Metastatic Non-Squamous NSCLC - Slides

P15. Phase II Prospective Study of Adjuvant Pembrolizumab in N2 Positive NSCLC Treated With Neoadjuvant CCRT Followed by Surgery - Slides

P15. Toripalimab and Platinum-Doublet Chemotherapy as Neoadjuvant Therapy for Potentially Resectable Non-Small Cell Lung Cancer - Slides

P16. Clonal Landscape Predicts Outcome in Lung Squamous Cell Carcinoma Patients with a Low Tumor Mutational Burden - Slides

P16. Atezolizumab, Bevacizumab and Chemotherapy (IMpower150) in Stage IV Non-Small Cell Lung Cancer: The Australian Experience - Slides

P16. SWItch Maintenance PEmbrolizumab in patients with Non Small Cell Lung Cancer (SWIPE): Final Analysis - Slides

P16. A Phase II Clinical Study Evaluating Camrelizumab Combined With Apatinib and Albumin Paclitaxel for Advanced Non-Small CellLung Cancer - Slides

P16. Real World Data of First-Line Treatment With Pembrolizumab for Highly PD-L1-Expressing NSCLC - Slides

P16. Comparison of Clinical Outcomes of Patients With Advanced NSCLC In Clinical Trials and in the Real World Received PD-1/PD-L1 Inhibitor - Slides

P16. ARC-10: Phase 3 Study of Zimberelimab ± Domvanalimab vs Standard Chemotherapy in Front-Line, PD-L1-High, Metastatic NSCLC - Slides

P17. KEYNOTE-407 China Extension Final Analysis: Pembrolizumab Plus Chemotherapy for the Treatment of Metastatic Squamous NSCLC - Slides

P17. RATIONALE 307: A Subgroup Analysis of Tislelizumab Plus Chemo vs Chemo Alone As 1L Treatment for Stage IIIB Advanced Sq NSCLC - Slides

P17. Sintilimab With Two Cycles Nab-Paclitaxel / Platinum as First Line Therapy for Advanced Squamous Non–Small-Cell Lung Cancer - Slides

P19. RATIONALE-303 Phase 3 Tislelizumab vs Docetaxel in Previously Treated Advanced NSCLC: China Subgroup Analysis - Slides

P19. Sintilimab Plus Docetaxel in Previously Treated Advanced NSCLC, Updates on Progression-Free and Overall Survival - Slides

P21. Selected ctDNA Panel Gene Sequencing for Neoantigen Discovery and Survival Prediction in Patients With Stage IV Non-Small Cell Lung Cancer - Slides

P21. Real-World Concordance Between Tumor Mutational Burden From Blood and Tissue in Lung Cancer and Other Cancers - Slides

P22. Combined Use of CYFRA 21-1, CA125 and CRP Predicts Survival of Metastatic NSCLC Patients With Stable Disease - Slides

P22. Role of Circulating Tumor Cell Subpopulations in Operable Non-Small Cell Lung Cancer Diagnosis and Prognosis - Slides

P22. Prospective Validation of an Eight Gene mRNA Signature in Plasma for the Diagnosis of Early Stage Lung Cancer - Slides

P22. Dynamic Monitoring of Blood Samples by PEAC Technology for Early-Stage Lung Cancer Patients After Surgery - Slides

P22. Prognostic Value of Circulating Tumor Cells in Patients With Small Cell Lung Cancer Receiving Front-Line Treatment - Slides

P23. Integration of Metabolomics and Transcriptomics to Reveal Metabolic Disorder in Early Lung Cancer for Non-invasive diagnosis - Slides

P23. Digital Multiplexed circRNA Analysis From Plasma-Derived Extracellular Vesicles of Lung Cancer Patients - Slides

P23. Novel Serum Extracellular Vesicles Based miR-153-3p Biomarker Combined to a Prediction Model for Determining Early-Stage Lung Cancer - Slides

P23. Serum Biomarkers Enhance Prognostic Value of Computed Tomography (CT) in Patients With Non-Small Cell Lung Cancer (NSCLC) - Slides

P23. Chromosome 3p22.1 and 10q22.3 Amplification in Different Subtypes of Lung Adenocarcinoma - Slides

P24. Turnaround Time and Variant Prevalence of a Blood-based KRAS Test in Patients With NSCLC - Slides

P24. Unique Efficacy of Ensartinib on Different ALK Fusion Subtypes Evaluated by Plasma ctDNA - Slides

P24. Dynamic Circulating Tumor DNA Interim Results From The ALKternate Clinical Trial - Slides

P24. Concordance of Tissue and Cell-Free DNA-Based Next-Generation Sequencing in Patients With Lung Adenocarcinoma - Slides

P24. Using Liquid Biopsies to Guide First-Line Therapy Decisions in Patients With Metastatic Non-Small Cell Lung Cancer - Slides

P24. Resistance Mechanisms Exploring of NSCLC With Central Nervous System Metastases Using Liquid Biopsy of Cerebrospinal Fluid: A Real-World Study - Slides

P24. An Ultra-Sensitive Protocol for ctDNA Mutation Detection With Application in Lung Cancers - Slides

P24. Lung Cancer Diagnosis in Absence of Adequate Tissue Molecular Analysis in Metastatic Disease by NGS Analysis of Plasma cfDNA - Slides

P24. Association Between Circulating EGFR Mutant Tumor DNA and Tumor Lesion Glycolysis in Patients with EGFR Mutated Metastatic Lung Adenocarcinoma - Slides

P24. Cell-Free Tumor DNA (ctDNA) Utility in Detection and Monitoring EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC) - Slides

P24. Biomarker Testing for Advanced Lung Cancer by Next-Generation Sequencing in Elderly Patients. - Slides

P24. Validation of Companion Diagnostics for the Identification of Patients with EGFR Exon20ins NSCLC for Amivantamab Therapy - Slides

P25. Concurrent Chemoradiotherapy With Cisplatin + S-1 for Locally Advanced Non-Small Cell Lung Cancer: IPD Meta-Analysis - Slides

P26. Detecting Oligo-Metastatic/Progressive Disease in Advanced EGFR-Mutant NSCLC: PET/CT and Conventional Imaging Methods - Slides

P26. A Phase II Trial of Neoadjuvant Osimertinib for Surgically Resectable EGFR-Mutant Non-Small Cell Lung Cancer: Updated Results - Slides

P27. Patterns of Care and Outcomes in Clinical T3N0M0 Non-Small Cell Lung Cancer Without Invasion of Other Structures - Slides

P27. Associating Cardiac Plaque Accumulation With Cardiac Toxicity and Overall Survival In Locally Advanced Non-Small Cell Lung Cancer - Slides

P27. Increase in Overall Survival for Locally Advanced NSCLC Patients From 2010 to 2018 - A Registry Based Study in Denmark - Slides

P27. Clinical Outcomes for Patients With Stage III NSCLC and STK11 or KEAP1 Genetic Alterations - Slides

P27. Multiscale NSCLC Tumor Growth Knowledge-Based Model Reproduces Tumor-Non-Progression under Gefitinib - Slides

P27. Pancoast Tumour Presenting as Lower Limb Weakness; Would You Recognise It? - Slides

P27. Accurate Positioning Technology for Lung Cancer Radiotherapy - Slides

P28. Real-World Experience (RWE) of Consolidation Durvalumab After Concurrent Chemoradiotherapy (CCRT) In Stage III NSCLC - Slides

P28. Beyond PACIFIC: Outcomes and Toxicity According to Durvalumab Dosing Schedule Every 2 versus 4 Weeks - Slides

P28. Durvalumab Adjuvant to Chemoradiation for Patients With Locally Advanced Non-Small Cell Lung Cancer: Real World Experience - Slides

P28. Pneumonitis With Durvalumab Following Concurrent Chemoradiotherapy - Slides

P29. Deformable vs. Rigid Registration in Evaluating Composite Doses to Central Organs at Risk in Thoracic Reirradiation - Slides

P29. Early GLS Changes Detection After Chemoradiation in Locally Advanced NSCLC - Slides

P29. Thoracic Organs at Risk (OARs) Contouring Variations and Consensus in Radiation Therapy for Non-Small Cell Lung Cancer - Slides

P29. Treatment Plan Parameters and Toxicity Following Chemoradiotherapy and High-Dose Radiotherapy in Stage III Non-Small Cell Lung Cancer - Slides

P29. Gross Tumor Volume Contouring Variations in Radiation Therapy of Non-Small Cell Lung Cancer - Slides

P29. Both Endostar and Amifostine Reduced All the Incidence of Pneumonitis Above Grade 2 in Chemoradiotherapy With Locally Advanced NSCLC - Slides

P29. A Phase Ib Trial of Neoadjuvant Low-Dose Radiation Therapy, Chemotherapy, and Durvalumab for Potentially Resectable Stage III NSCLC - Slides

P29. Evaluation of the Prognostic Marker of PD-L1 Expression After Combined Radiochemotherapy in Patients With NSCLC Stage III

P30. Extended Resections for Advanced Stages T3/T4 NSCLC After Neoadjuvant Treatment: Conclusions of SAKK Pooled Analysis (16/96, 16/00, 16/01) - Slides

P30. Salvage Surgery in Patients With Locally Advanced Non-Small Cell Lung Cancer – Outcomes and Longtime Results - Slides

P30. Impact of Visceral Pleural Invasion (VPI) and lymphovascular Invasion (LVI) on Stage I Non-Small Cell Lung Cancer (NSCLC) Outcomes - Slides

P30. Clinical Research on Patients With Surgically Resected Lung Adenocarcinoma Lesions: Are Heterogeneous GGNs Different From Part Solid Nodules? - Slides

P31. Impact of COVID-19 on Lung Cancer Diagnosis and Treatment: A Retrospective Chart Review - Slides

P31. Impact of COVID-19 Pandemic in Spanish and Portuguese Lung Cancer Patients - Slides

P31. The Impact of the COVID-19 Pandemic on a Thoracic Tumor Unit of a Tertiary Hospital in Spain - Slides

P31. Global Impact of COVID-19 on NSCLC Surgery: Initial Analysis of the CovidSurg-Cancer Study - Slides

P31. SARS-CoV-2 and Lung Cancer: Pandemic Impact in Diagnosis, Staging and Management - Slides

P31. Impact of Covid-19 Infection on Lung Cancer Patients: Experience in Latin-American Country ACHOCC-19L Study - Slides

P32. Clinical Screening for COVID-19 in Asymptomatic Patients With Lung Cancer: Brazilian Experience From a Single Institution - Slides

P32. 2020 in Hindsight: Newly Diagnosed Lung Cancer Patients in the Time of COVID-19 at a Tertiary Canadian Cancer Centre - Slides

P33. Air Leak Due COVID-19 in a Lung Cancer Patient - Slides

P33. Day Case Thoracocoscopy With IPC Insertion - Slides

P34. 6-Weekly vs 3-Weekly Pembrolizumab – Toxicities and Tolerance in The COVID-era - Slides

P34. The Inhibitory Effect of Cisplatin, Paclitaxel, and Pemetrexed on the Growth of PC9GR Cells During the COVID-19 Pandemic - Slides

P34. Lung Cancer Patients and COVID-19 in a District General Hospital in the UK - Slides

P34. Chemo-Immunotherapy in Non-Small Cell Lung Cancer (NSCLC) – Real World Data from a Tertiary Oncology Centre - Slides

P34. Three Birds, One Stone: IVIG Use in Hypogammaglobulinemia, Checkpoint Inhibitor Pneumonitis, and Persistent COVID-19 - Slides

P34. Antiproliferative Effects of Paclitaxel on PC9-MET Cells During the Coronavirus Disease 2019 Pandemic - Slides

P35. YB-1 is a Key Player in Aggressive Behaviour and Chemoresistance in Mesothelioma - Slides

P36. Primary Acinic Cell Carcinoma of Bronchial Ground Origin: A Case Report - Slides

P36. A Case of Recurrent Giant Malignant Solitary Fibrous Tumour of the Pleura: An Elephant in the Room? - Slides

P36. Rapidly Progressed Anaplastic Carcinoma in the Anterior Mediastinum Successfully Treated With Gene-Targeted Therapy - Slides

P37. The Results of Multimodal Treatment With Extrapleural Pneumonectomy for Female Epithelioid Malignant Pleural Mesothelioma - Slides

P37. Improving Outcomes in Malignant Pleural Mesothelioma in an Integrated Health System - Slides

P37. The Epidemic of Malignant Mesothelioma in China: A Prediction of Incidence During 2016-2030 - Slides

P38. p40 and p63 Immunohistochemistry in the Diagnostic Consideration of NUT Carcinoma in the Lung - Slides

P38. The Prognostic Role of Neutrophil to Lymphocyte Ratio (NLR) In Lung Metastasectomy for Colorectal Cancer: A Meta-Analysis - Slides

P39. Long-Term Outcomes and Characteristics of Unresectable Locally Advanced Thymic Malignancies - Slides

P39. Does Neo-Adjuvant Chemotherapy Help in Locally Advanced Thymic Maliganancy? - Slides

P39. Primary Mediastinal Germ Cell Tumors: A 15-Years Experience Treatment in Rajavithi Hospital, Thailand - Slides

P39. Thymic Epithelial Tumors: The Importance of Invasive Investigation to Adequate Diagnosis - Slides

P39. Outcomes of Videothoracoscopic Thymectomy for Treatment Large-Sized Thymomas - Slides

P40. Maintenance Anlotinib After Induction Therapy With Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer: A Phase 2 Study - Slides

P40. Pemetrexed in Advanced-stage Lymphoepithelioma Carcinoma of Lung - Slides

P40. Palliative Radiotherapy Decreased Circulating White Blood Cells in Patients With Stage IV Lung Cancer - Slides

P40. CNS Adverse Events and Survival in Patients with NSCLC Brain Metastases Treated With Concurrent Radiation and Immunotherapy - Slides

P40. A Real-World Study: Efficacy and Safety of Anlotinib for Advanced Non-Small Cell Lung Cancer - Slides

P40. Immunotherapy Toxicity in Lung Cancer & the Impact of Thoracic Radiation Therapy - Slides

P40. Bone-Targeted Agents Improve Survival in High Bone Tumor Burden Advanced Non-Small-Cell-Lung Cancer Patients Treated With PD-(L)1 Inhibitors - Slides

P40. Using Real World Data to Identify a Patient Cohort Who Require Prehabilitation to Improve Treatment Rates for Stage 3 NSCLC - Slides

P40. Brain Metastases in Patients With Non-Small Cell Lung Cancer Treated With Immunotherapy. Real World Data From a Tertiary Hospital in Spain - Slides

P40. Trimodality Therapy Protocol in 144 Superior Sulcus Patients: Good Results Even for Extended Resections and Indications - Slides

P40. Cardiotoxicity in Lung Cancer Patients Treated With Immune-Checkpoints Inhibitors - Slides

P40. Lung Cancer 5-Year Survival in Croatia - Our Experience - Slides

P40. Efficacy and Safety of Endostar Combined With Camrelizumab and Chemotherapy in Treatment of Advanced NSCLC: A Multi-Center Retrospective Study - Slides

P40. Proton Pump Inhibitors, Prior Therapy and Survival in Patients Treated With Immune Checkpoint Inhibitors for Advanced NSCLC - Slides

P40. Real-World Data and Racial Outcomes for NSCLC in The Chemo-Immunotherapy Era - Slides

P40. Palliative Radiotherapy Decreased K+ and Ca2+of the Blood in Patients With Stage IV Lung Cancer - Slides

P40. Second Line Immunotherapy After Progression on a Different First Line Immunotherapy in Advanced Non-Small Cell Lung Cancer With Focus On Elderly - Slides

P40. Efficacy and Toxicity of Third-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer - Slides

P40. Real-Life Analysis of Immunotherapy as the Second or Later Lines Treatment in Patients With Metastatic Non-Small Cell Lung Cancer - Slides

P41. Abscopal Response Induced by Thermal Ablation in Advanced NSCLC Patients Failed From Immunotherapy: Preliminary Result From a Phase 2 Trial - Slides

P41. Surgery for Small Pulmonary NUT Carcinoma: Case Report - Slides

P42. Tumor Size is an Independent Prognostic Factor after Pulmonary Metastasectomy - Slides

P42. Prognostic Indicators for Conventional Chemotherapy Response in Advanced Non-Small Cell Lung Cancer Patients in Resource-Limited Country - Slides

P42. Predictive Factors of Response to PD-(L)1 Inhibitors in Patients With Advanced Non-Small Cell Lung and High PD-L1 Expression - Slides

P42. Prognosis Factors in Advanced Lung Cancer Patients Treated With Checkpoint Inhibitor-Based Immunotherapy - Slides

P43. Three-Dimensional Virtual Planning for Nodule Resection in Solid Organs: A Systematic Review and Meta-Analysis - Slides

P43. Inconsistencies Within Biomarker Test Reports Provide Opportunities for Future Patient Education - Slides

P43. LUPA-01: An Observational Study to Monitor Lung Cancer Patients’ Activity and Assess Performance Status through a Wearable Device in Spain - Slides

P44. Clinical Predictive Markers of Response to Immunotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC). - Slides

P44. Prevalence, Onset, and Severity of Renal Impairment With Pemetrexed/Carboplatin +/- Pembrolizumab in Metastatic Non-Squamous NSCLC - Slides

P45. Therapeutic effectiveness of Lorlatinib After Alectinib in Japanese Patients With ALK-Positive NSCLC in Real-World - Slides

P45. Tepotinib in Patients with MET exon 14 (METex14) Skipping NSCLC as Identified by Liquid (LBx) or Tissue (TBx) biopsy - Slides

P45. Phase II Study of Brigatinib in ROS1 Positive Non-Small Cell Lung Cancer (NSCLC) Patients Previously Treated with Crizotinib: Barossa Cohort 2 - Slides

P45. Sequencing of PD-1 Inhibitors and TKIs in Metastatic NSCLC with MET Exon 14 Skipping Mutation May Influence Survival - Slides

P45. Overall Survival From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1+ Advanced Non-Small-Cell Lung Cancer - Slides

P45. Real-World Clinically-Relevant Toxicities of ALK TKIs in a Cohort of Patients With Advanced/Metastatic ALK+ NSCLC - Slides

P45. Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety Data from a Phase 2 Study in China - Slides

P45. Real-World Sequencing of ALK-TKIs in Advanced Stage ALK-positive NSCLC patients in Canada - Slides

P45. Effects of ALK Tyrosine Kinase Inhibitors in the Treatment of Metastatic NSCLC: A Systematic Review and Meta-Analysis - Slides

P45. Co-occurring CDKN2A/B Alteration Is Associated With Worse Survival Outcomes in Advanced ALK-Positive Non-Small Cell Lung Cancer - Slides

P45. Renal Function Change During Alectinib in ALK Rearranged Non-Small Cell Lung Cancer: A Retrospective Multicentre Analysis - Slides

P45. Efficacy and Safety of Crizotinib in Real-World ROS1-rearranged NSCLC: A Retrospective Canadian Cohort - Slides

P45. Real-World Experience on Treatment of crizotinib in ALK/ROS1/MET Alterated Non-Small-Cell Lung Cancer Patients in China - Slides

P45. Clinical Outcomes, Long-Term Survival and Toleration With Sequential Therapy of First-Line Crizotinib Followed by Alectinib in ALK+ NSCLC - Slides

P46. Progression After Targeted-therapy – An EGFR Case Report - Slides

P46. Impact of Real-World DNA- and RNA-Based Rebiopsy Testing in EGFR-Mutated NSCLC Progressing on Osimertinib. - Slides

P46. Targeting ROS1 Gene Rearrangement by Crizotinib as Neoadjuvant Treatment Before Definitive Radiotherapy in Locally Advanced NSCLC - Slides

P46. Different Effects of Crizotinib Treatment in Three Lung Adenocarcinoma Patients With Various ROS1 Fusion Variants - Slides

P46. Durable Response to Double Dose Osimertinib 160mg in EGFR-Mutated Non-Small Cell Lung Cancer With Brain Metastases - Slides

P46. Response of an Advanced Lung Cancer Mass to Targeted Therapy - Slides

P46. Afatinib-Related Pneumonitis in Metastatic EGFR-Positive NSCLC - Slides

P47. SGNTUC-019: Phase 2 Study of Tucatinib and Trastuzumab in Solid Tumors: Lung Cancer Cohorts (Clinical Trial in Progress) - Slides

P47. EV-202: Phase 2 Study of Enfortumab Vedotin for Previously Treated Advanced Solid Tumors Including Non-Small Cell Lung Cancer - Slides

P47. Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met+ Advanced Non-Small Cell Lung Cancer: Stage 2 - Slides

P47. TROPION-Lung02: Datopotamab Deruxtecan (Dato-DXd) Plus Pembrolizumab and Platinum-Based Chemotherapy in Advanced NSCLC - Slides

P47. A Phase 2 Study of Datopotamab Deruxtecan (Dato-DXd) in Advanced NSCLC With Actionable Genomic Alterations (TROPION-Lung05) - Slides

P47. TROPION-Lung04: Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab and Platinum-Based Chemotherapy in Advanced NSCLC - Slides

P47. KEAPSAKE Study of Telaglenastat vs Placebo Plus Standard-of-Care in 1L KEAP1/NRF2-Mutated Non-Squamous Metastatic NSCLC - Slides

P47. A Phase II, Single-arm, Multicenter, Efficacy of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With EGFR Mutated NSCLC - Slides

P47. Tepotinib + Osimertinib for EGFR-Mutant NSCLC with Resistance to First-Line Osimertinib Due to MET amplification: INSIGHT 2 - Slides

P47. Neoadjuvant Osimertinib in EGFR-Mutant Stage IIIA/B NSCLC - A Phase 2 Open-Label Pilot Study - Slides

P47. COMPEL: Chemotherapy With/Without Osimertinib in Patients With EGFRm Advanced NSCLC and Progression on First-Line Osimertinib - Slides

P47. ALKternate: A Proof of Concept Study in ALK-Rearranged NSCLC Alternating Lorlatinib With Crizotinib After Disease Progression - Slides

P47. First-in-Human, Dose Escalation and Expansion Study of MT-6402 in Patients With PD-L1 Expressing Advanced Solid Tumors - Slides

P47. Study Design of SCORPION: Multi-Center, Phase II Study Following Platinum-Based Chemotherapy Plus ICIs in Patients with NSCLC - Slides

P47. A Phase IA Study of Ceritinib + Trametinib in Patients With Advanced ALK- or ROS1- Rearranged NSCLC: Preliminary Results - Slides

P47. Preliminary Efficacy and Safety Results About a Phase II Trial of Afatinib and Bevacizumab in Untreated NSCLC Harboring EGFR Sensitive Mutations - Slides

P47. Capmatinib vs Docetaxel in Pretreated Patients With MET Exon 14 Skipping–mutated Stage IIIB/IIIC or IV NSCLC (GeoMETry-III) - Slides

P47. Almonertinib With Radiotherapy vs Concurrent Chemoradiotherapy in Unresectable Stage III EGFR-mutant NSCLC (ADVANCE Trial) - Slides

P48. Anlotinib Plus Docetaxel vs Docetaxel for 2nd-Line Treatment of EGFR negative NSCLC (ALTER-L018): A Randomized Phase II Trial - Slides

P48. Real-World Data of Dacomitinib in EGFR TKI-Naïve Patients With Advanced Epidermal Growth Factor Receptor-positive Non-small Cell Lung Cancer - Slides

P48. EGFR Germline Mutations in Chinese Lung Cancer Patients: A Single Institutional, Retrospective Study - Slides

P48. Is Relapse-Free Survival at 2-Years an Appropriate Surrogate for Overall Survival at 5-Years in EGFR-mutated Resected NSCLC? - Slides

P48. A Network Meta-Analysis (MA) of First-Line Lung Cancer Treatment With Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) - Slides

P48. Real-World Impact of Upfront Osimertinib in Reducing Health Resource Utilization by Preventing Brain Metastases - Slides

P48. The Efficacy and Clinical Survival Outcome of Different First-Line Treatments in EGFR Mutant Non-Small Cell Lung Cancer With Brain Metastases - Slides

P48. Body Mass Index Predicts Benefit From Adding Metformin to EGFR-TKIs in Patients With Lung Adenocarcinoma: Subanalysis From an RCT - Slides

P48. Efficacy of EGFR-TKIs vs TKIs Plus Chemotherapy as First-Line Treatment in EGFR-Mutation Lung Adenocarcinoma With Liver Metastases - Slides

P48. ctDNA Dynamic Detection Reveals the Advantages of EGFR Tyrosine Kinase Inhibitors Combined With Chemotherapy in NSCLC Patients - Slides

P48. Concurrent Chemotherapy and First-Generation EGFR-TKI as First-Line Treatment in Advanced Lung Adenocarcinoma Harboring EGFR Mutation - Slides

P48. Clinical Factors Associated With Treatment Outcomes in EGFR Mutant Non-Small Cell Lung Cancer Patients. Real Life Experience in Argentina - Slides

P48. Metastatic NSCLC -Re-Challenging With Fist Generation TKI After a Drug Free Holiday After Resistance to 3rd Generation TKI - Slides

P48. EGFR Mutated Non-Small Cell Lung Cancer Treatment Pathway – What Is the Best Way? - Slides

P48. The Effect and Safety of Anlotinib as a Third Line or Further Therapy in Non-Small Cell Lung Cancer Patients With Liver Metastasis - Slides

P48. Real-World Study of Patients With EGFR Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer Treated With First-Line Osimertinib - Slides

P49. Drug Holiday Based on Minimal Residual Disease Status After Local Therapy Following EGFR-TKI Treatment for Patients With Advanced NSCLC - Slides

P50. RELAY, Erlotinib Plus Ramucirumab in Untreated, EGFR-Mutated, Metastatic NSCLC: Outcomes by EGFR Exon 19-del Variants - Slides

P50. A Real-World Cohort Study of EGFR TKIs in Patients with NSCLC with Uncommon EGFR mutations (UpSwinG) - Slides

P50. Amivantamab in Combination With Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) - Slides

P50. Natural History and Real-World Treatment Outcomes for NSCLC Patients with EGFR Exon 20 Insertion Mutation: An IASLC- ASCO CancerLinQ Study - Slides

P50. First-Line Therapy in NSCLC harbouring EGFR or HER2 Exon 20 Insertion Mutation. Hunting for the Best Candidate - Slides

P50. Afatinib Treatment Response in Advanced Lung Adenocarcinomas Harboring Uncommon Mutations in Chinese Population - Slides

P50. Targeting HER2 or EGFR Exon 20 Insertion Mutation in Lung Cancer - A Case Series from India - Slides

P51. Tepotinib Plus an EGFR TKI in Patients with EGFR-mutant NSCLC and Resistance to EGFR TKIs Due to MET Amplification (METamp) - Slides

P51. Oritinib (SH-1028), a Third-generation EGFR-TKI in Advanced NSCLC Patients with Positive EGFR T790M: Results of a Single-arm Phase Ib Trial - Slides

P51. Pattern of Disease Progression on Osimertinib and Subsequent Treatment in Patients with EGFR- Mutated Non-Small Cell Lung Cancer - Slides

P51. Sequential Afatinib and Osimertinib in Patients With Advanced EGFRm+ NSCLC and Acquired T790M: The Real-World UpSwinG study - Slides

P51. Outcomes of First-Line TKI Treated Advanced NSCLC with Distinct Types of EGFR Mutations: Brain Metastasis and de Novo T790M - Slides

P51. Small Cell Transformation of Non Small Cell Lung Carcinoma: Tissue Biopsy Is Here to Stay! - Slides

P52. Understanding Treatment Preferences of Patients With KRAS p.G12C[LC1] [MK2] – Mutated Advanced Non-Small Cell Lung Cancer - Slides

P52. High SHP2 Expression Determines the Efficacy of PD-1/PD-L1 Inhibitors in Advanced KRAS Mutant Non-Small Cell Lung Cancer - Slides

P52. Efficacy of Sotorasib in KRAS p.G12C-Mutated NSCLC with Stable Brain Metastases: A Post-Hoc Analysis of CodeBreaK 100 - Slides

P52. Dual RAF/MEK Inhibitor VS-6766 for Treatment of KRAS Mutant NSCLC: Novel Combinations Targeting G12C or G12V Variants - Slides

P53. Clinical Application of NGS Technology. Therapeutic Possibilities and Future Perspectives - Slides

P53. Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase (TRK) Fusion-Positive Lung Cancer - Slides

P53. Local Therapies vs. Specific TKIs as the Initial Treatment for Oligo-Recurrent Lung Adenocarcinoma With Driver Mutations - Slides

P53. Inhibition of Tumor Cell Intrinsic Complement Regulatory Proteins Leads to Decreased Tumor Growth in a Mouse Model of NSCLC - Slides

P53. A Multi-Phase Quality Initiative to Improve Processes of Care for Non-small Cell Lung Cancer (NSCLC) in US Community Cancer Centers - Slides

P53. Clinical and Genomic Insights Into of Chinese Lung Cancer Patients with HER2 Amplification - Slides

P53. Concomitant Fibrates and Immunotherapy in Non-Small Cell Lung Cancer Patients in the Veterans Health Administration - Slides

P54. Analysis of the Support Needs of Lung Cancer Patients - Slides

P54. Bilateral Indwelling Pleural Catheters - Slides

P54. Detecting Elevated Risk of Diminished Quality of Life Among Lung Cancer Patients by Using Wearable Devices - Slides

P54. Stereotactic Radiotherapy for Brain Metastases in Patients With Lung Cancer: Cyberknife Experience - Slides

P54. The FITNESS Study: Geriatric Assessment, Treatment Toxicity, and Biospecimen Collection Among Older Adults With Lung Cancer - Slides

P55. Standard of Care Disparity in a Global Cancer Support Group: Examining an Advocate Survey to Inspire Change. - Slides

P55. Robotic Surgery in Canada: Are Patients Willing to Pay Out-of-Pocket? - Slides

P55. Results of The First Survey Using EORTC QLQ INFO25 on Information Acquisition and Satisfaction of Lung Cancer Patients in Japan - Slides

P56. Semiquantitative Assessment of Tumor Spread Through Air Spaces in a Historic Cohort of Lung Adenocarcinomas Following Open Surgical Resection - Slides

P56. Novel Low Malignant Potential/Vascular Invasive (LMPVI) Grade is Superior to WHO 2015 and IASLC 2020 Adenocarcinoma Grade - Slides

P56. Prognostic Value of Tumor Spread Through Air Spaces in Patients With Lung Adenocarcinoma after Radical Surgery - Slides

P56. Pathological Features & Prognosis of NSCLC Patients With Enteric Adenocarcinomas Without Expression of TTF-1 and Napsin A - Slides

P56. Detection Rate and Prognosis of Nodal-Micro Metastasis by IHC in pN0 Resectable Non-Small Cell Lung Cancer - Slides

P56. Clinical Significance and Potential Function of S100A10 in Lung Adenocarcinoma - Slides

P57. Immunotherapy Fits Everyone? Prognostic Markers for Immune-checkpoint-Inhibitor (ICI) in Non-small Cell Lung Cancer (NSCLC) - Slides

P57. Integration of Systemic / Tumor PD-L1 as a Predictive Biomarker of Clinical Outcome in Advanced NSCLC Patients Treated With Anti-PD-(L)1 Agents - Slides

P57. Cellular Engagement and Interaction in the Tumor Microenvironment (TME) Predicts Response to ICI in Metastatic NSCLC - Slides

P57. Predicting Treatment Response to 1st- line Pembrolizumab in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients with High PDL1 Expression - Slides

P57. Low Variant Allele Frequency of TP53 as a Biomarker for PD-1/PD-L1 Inhibitors in Lung Adenocarcinoma - Slides

P57. EGFR Mutational Status and PD-L1 in Early-Stage Brazilian Non-Small-Cell Lung Cancer

P57. The Scottish Immunotherapy Prognostic Score (SIPS) Predicts Response to First-Line Pembrolizumab for Metastatic Non-Small Cell Lung Cancer - Slides

P57. Common Oncogenic Driver Mutations and PD-L1 Expression in Non-Small Cell Lung Cancer of Smokers and Never Smokers - Slides

P57. Clinicopathological Analysis of Anti-Tumor Immunology-Related Factors After Chemoradiotherapy for Lung Cancer - Slides

P57. The Role of Serum Proteomic Signature in Predicting Survival by PD-L1 Status in Patients With Non-Small Cell Lung Cancer Receiving Immunotherapy - Slides

P57. Clinical and Molecular Features of Chinese Lung Cancer Patients With Germline Mismatch Repair Gene Mutations - Slides

P57. Correlation of TP53/KMT2C co-mutation and Tumor Microenvironment in Lung Cancer - Slides

P57. LRMP Associates With Immune Infiltrates and Acts as a Prognostic Biomarker in Lung Adenocarcinoma - Slides

P57. Safety and Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients With Low Creatinine Clearance Rate - Slides

P58. Dysbiosis of Fecal Microbiome in Advanced Non-Small-Cell Lung Cancer - Slides

P59. Clinical Characteristics of Patients With MET Amplification-Positive NSCLC After EGFR-TKI Therapy - Slides

P59. Profile of Next-Generation Sequencing (NGS) on MET exon 14 Skipping Mutation and MET Amplification in Lung Cancer: A Calibration Project in China - Slides

P59. Comparison of Two RNA-Based Platforms for Detection of Fusions and Met Splicing Variant in Non Small Cell Lung Cancer Samples - Slides

P59. Integration of Molecular Cancer Classification and NGS to Identify Metastatic Cancer Patients Eligible For Lung Cancer Directed Therapy - Slides

P59. Prognostic Nutritional Index in Real-World Patients Receiving Systemic Therapy for Driver Mutation-Positive Metastatic NSCLC - Slides

P59. Mutation Profile of BRAF in Chinese Non-Small Cell Lung Cancer Patients - Slides

P59. Identifying the Origin of Lung-Specific Cancer of Unknown Primary Based on Comprehensive Genomic Profiling Optimized With DNA Methylation - Slides

P59. Landscape of Targetable Genomic Alterations in Hispanic/Latinx Patients With Non-Small Cell Lung Cancers - Slides

P59. A Sneak Peak in the Future World of EGFR Mutations: ML Based PFS Differences Between Del 19 and L858R - Slides

P59. Real-World Data of NGS Diagnostic Biomarker Testing for Lung Cancer Patients in Japan - Slides

P59. KRAS Mutation Subtypes in Non-Small Cell Lung Cancer and Clinical Outcomes: A Single Centre Experience - Slides

P59. The Prediction Performance of TP53 / RB1 Co-Mutation on Small-Cell Lung Cancer Transformation in Patients With Non-Small Cell Lung Cancer - Slides

P59. Concordance and Performance of ddPCR Compared to NGS for The Detection of KRAS G12C Mutation - Slides

P59. Is CD73 Expression a Druggable Mechanism of Resistance in EGFR-TKI-Treated EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)? - Slides

P60. Investigation of Aurora Kinase A as a Potential Biomarker of Radiation in Non-Small Cell Lung Cancer (NSCLC) - Slides

P60. Polymorphisms of APE1(T444G), hOGG1(C977G), XRCC1(G839A), XPD(T2251G), XPG(G3310C), XPC(A2815C) Genes in Lung Cancer Patients - Slides

P60. Transcriptome and Genome Profiles of Metastatic Lung Cancers Highlighted Predictive Power of Infection-Related Model in Metastasis - Slides

P60. TTF1 Expression in Advanced Lung Adenocarcinoma and Survival Outcome: An Observational Study - Slides

P60. Radiomic Signature to Predict Outcomes in EGFR-Mutant Non-Small Cell Lung Cancer - Slides

P60. Systematic Variant Profiling Delineates the Radiogenomic Landscape of Cancer - Slides

P60. Comprehensive Genomic Profiling of Microsatellite Instability-High Lung Cancer in China - Slides

P60. Systemic Immune-Inflammatory Index (SII) as a Biomarker for Metastatic Non-Small Cell Lung Cancer - Slides

P60. Real-World Readiness of US Laboratories to Test Metastatic NSCLC Patients for Rare Actionable Genomic Variants by NGS - Slides

P60. A 27-Gene IO Assay to Capture the Tumor Immune Microenvironment Is Associated With Response in Metastatic and Primary Tumors - Slides

P60. Trends in Molecular Testing for Metastatic Non-Small Cell Lung Cancer in The US Oncology Network Community Practices - Slides

P60. Prevalence of c-Met overexpression (c-Met+) and Impact of Prior Lines of Treatment on c-Met Protein Expression in NSCLC - Slides

P60. MYLUNG Consortium: Molecularly Informed Lung Cancer Treatment in a Community Cancer Network. Pragmatic Prospective RWR Study - Slides

P61. Intelligence Assistant Million Early-Stage Lung Cancer Research Program in China - Slides

P61. The Use of PLCOm2012 vs PLCOm2012noRace Risk Prediction Models in a UK Lung Cancer Screening Programme - Slides

P61. Comparison of the Sensitivity of Different Screening Algorithms to Select Lung Cancer Patients for Screening in a Cohort of German Patients - Slides

P61. Disparities Related to Low-Dose Computed Tomography Screening Eligibility Criteria for Lung Cancer: A Single-Center Analysis - Slides

P61. Time to Loosen Up: Liberalizing Lung Cancer Screening Guidelines Might Save More Lives - Slides

P61. Participants With Family History of Cancer Have a Higher Participation Rate of Low-Dose Computed Tomography for Lung Cancer Screening - Slides

P61. Advancing Health Equity in Cancer Care: The Lived Experiences of Poverty and Access to Lung Cancer Screening - Slides

P61. A Light Gradient Machine-Enabled Radiomics Model for Survival Prediction in Non-Small-Cell Lung Cancer-Not Otherwise Specified - Slides

P61. Feasibility of Lung Cancer Screening With Low-Dose Computed Tomography in a Rural Community Setting; An 8-Year Experience - Slides

P61. Swiss Pilot Low-Dose Computed Tomography Lung Cancer Screening Study - Slides

P62. PREVALUNG: Evaluation of Lung Cancer Prevalence in Patients With Smocking-associated Atherosclerotic Cardiovascular Diseases - Slides

P62. A Predictive Model to Guide Brain MRI Surveillance in Patients With Metastatic Lung Cancer: Impact on Real World Outcomes - Slides

P62. Survival After Distant Recurrent Versus De Novo Stage IV Metastatic Lung Cancer Under Low-Dose Computed Tomography Screening - Slides

P62. Neoteric Small Extracellular Vesicles Based Biomarker for Predicting Cancerous Sub-Solid Nodules of Lung - Slides

P62. Identifying Risk-Factors for Lung Cancer Diagnosis After Detection of Incidental Lung Nodules - Slides

P62. A Radiomics Nomogram for Preoperative Prediction of Occult Lymph Node Metastasis in Early-Stage Solid Lung Adenocarcinoma - Slides

P62. Pre-surgical Assessment of Mediastinal Lymph Node Metastases in Stage IA Non-small-cell Lung Cancers - Slides

P62. A Prospective Cohort Evaluation of the Sensitivity and Specificity of the Chest X-Ray for the Detection of Lung Cancer in Symptomatic Adults - Slides

P62. AI-Based Three-Dimension Reconstruction for Pulmonary Nodules -New Auxiliary Exploration for Thoracic Surgery - Slides

P62. Germline Genetic Testing in Patients with Lung Cancer in a Mexican Center - Slides

P63. Lurbinectedin in Pre-Treated Patients With Small Cell Lung Cancer and Malignant Pleural Mesothelioma in a Real World Setting - Slides

P63. Exposure-Response Analysis of Lurbinectedin Alone or With Doxorubicin in Overall Survival in Small Cell Lung Cancer - Slides

P63. Very Limited SCLC Benefits From Surgery and Adjuvant Chemotherapy – A Large Retrospective Analysis - Slides

P63. Minimum Number of Lymph Node Dissections for Resectable Early-Stage Small Cell Lung Cancer - Slides

P63. Treatment Pattern in Small Cell Lung Cancer: A Real-world Observational Study in the Era of Immune Checkpoint Inhibitors - Slides

P63. Immunotherapy Improved Pathological Response for Resectable Limited Stage Small Cell Lung Cancer- A Case Serial - Slides

P63. Real World Predictors for Long Term Survival in Stage IV Small Cell Lung Cancer Treated With Standard of Care Chemotherapy - Slides

P63. Real-World Utilization of Immune Checkpoint Inhibitors in Extensive Stage Small Cell Lung Cancer in Community Settings - Slides

P63. Surgical Management of Cushing's Syndrome Secondary to Lung Carcinoid Tumors: Changing Perspectives - Slides

P63. Safety of Simultaneously Performed Radiotherapy in Patients With Small-Cell Lung Cancer Undergoing Atezolizumab Treatment - Slides

P63. Real-World Survival Outcomes of Patients with Limited Stage Small Cell Lung Cancer (LS-SCLC) by Choice of Platinum Chemotherapy - Slides

P63. Radiotherapy for Small Cell Lung Cancer in Current Clinical Practice Guidelines - Slides

P63. Long Term Survival Characteristics in SCLC Patients Receiving Atezolizumab and Chemotherapy - Slides

P63. Three Weekly Irinotecan for Refractory/Relapsed Small Cell Lung Cancer - Slides

P63. Clinical Analysis of 89 Female Patients With Small Cell Lung Cancer - Slides

P64. The Canadian Small Cell Lung Cancer Database (CASCaDe): A Multi-Institutional Real-World Evidence Collaboration - Slides

P64. EMERGE 402 Phase 4 Observational Study: Safety and Outcomes in Patients With SCLC Receiving Treatment With Lurbinectedin - Slides

P64. A Phase II Single-Arm Trial of Apatinib as Maintenance Treatment Following First-Line Chemotherapy in Extensive Stage Small Cell Lung Cancer - Slides

P65. Are Serum Markers Useful In Patients With Resected Pulmonary High-Grade Neuroendocrine Tumors? - Slides

P66. Characterize the Heterogeneity of the Immunophenotype in Different Neuroendocrine (NE) Subtypes of Small-Cell Lung Cancer (SCLC) - Slides

P66. The Prognostic Implication of hes1 Protein Expression in Resected Small Cell Lung Cancers of 247 Cases - Slides

P66. The Functional Role of TGF-β Signaling in SCLC Heterogeneity and Metastasis - Slides

P66. A Multimodal Biomarker Predicts Dissemination of Bronchial Carcinoid - Slides

P66. Correlation Between Expression of Immune Cell-Related Molecular Markers and Prognosis in Small Cell Lung Cancer (SCLC) - Slides

P66. GPNMB Associates With Inferior Prognosis in SCLC Patients Through Promoting Tumor Cell Metastasis - Slides

P66. ASCL1 and DLL3 Expression and Their Clinicopathological Implications in Surgically Resected Pure Small Cell Lung Cancer - Slides

P66. Differential Expression of INSM1 Between Pure SCLC and LCNEC After Surgical Resection and Its Clinicopathological Significance - Slides

P66. Differential Orthopedia Homeobox (OTP) Expression in Pulmonary Carcinoids is Regulated Through Methylation - Slides

P67. Cough in Patients After Thoracic Surgery: A Pilot Study - Slides

P67. Long-term Follow-up Data of Respiratory Function in Patients with Lung Cancer Undergoing Surgery - Slides

P68. Tumor‑Derived Exosomal miRNA-190b-5p Induces Microglia M2 Polarization to Promote Brain Metastasis of Lung Cancer - Slides

P68. Losartan Enhances Lung Squamous Cell Carcinoma’s Sensitivity to Cisplatin Treatment By Promoting Mesenchymal to Epithelial Transformation - Slides

P68. An AI Workflow to Detect and Report Tumor Cell Proportion of H&E-Stained Tissue Samples - Slides

P68. Molecular Mechanism of MK2 Promoting Lung Adenocarcinoma Progression by Phosphorylating Transcription Regulator CRABP2 - Slides

P68. Human Lung Carcinoma Primary Cultures From Malignant Pleural Effusions as a Tool for Drug Screening and Personalized Therapy - Slides

P68. Development and Validation of an NGS-Based MSI Detection Method - Slides

P68. Long Non-Coding RNA linc00665 Inhibits CDKN1C Expression by Binding to EZH2 and Affects Cisplatin Sensitivity of NSCLC - Slides

P68. ERK3/MAPK6 Does Not Contribute to Cell Proliferation in NSCLC - Slides

P68. Precision Cut Lung Slices Models for Lung Cancer Chemoprevention Investigations - Slides

P68. PFN1 Induces Tumor Metastasis Through Promoting Secretion of Microvesicles By ROCK I/p-MLC Pathway in Non-Small Cell Lung Cancer - Slides

P68. Correlation of CD26 With Pro-Fibrotic Mediators in Lung Tumors - Slides

P68. Sensitivity to Statin in EMT-Induced NCI-H322M Cells is Further Enhanced by Simultaneous Downregulation of HMGCR Expression - Slides

P68. Lung Cancer in Young Patients Under 45 Years: A French Study - Slides

P68. Effect of GH / IGF1 System on Lung Cancer Cells A549 - Slides

P68. Exosome-Mediated Transfer of SERPINE2 Regulates Non-Small Cell Lung Cancer Cells Repopulation After Ionizing Radiation - Slides

P68. Relationship Between Cholesterol Synthesis in Cancer Cells and Anticancer Effect of Statins - Slides

P69. The Role of the Pregnancy Associated Protein Glycodelin and Its Influence on the Immune System in Non-Small-Cell Lung Cancer - Slides

P69. Immune-Related Genomic Features in Non-Small-Cell Lung Cancer - Slides

P70. KRAS G12C Mutations Among NSCLC Patients Present With a High Intrerregional Variation, Indicating a Population Substructure - Slides

P70. Clinicopathological and Genetic Ancestry Impact of TP53 Mutations in Brazilian Lung Adenocarcinoma Patients

P70. Computational Omics Biology Model (CBM) Identifies Amplifications of Chromosome 6p to Predict Chemotherapy Resistance - Slides

P70. Results From a Patient Avatar Program Utilizing Murine Xenografts and Organoids After Neoadjuvant Therapy for Operable NSCLC - Slides

P70. Identification of Germline Mutations in Young Never Smokers With Lung Adenocarcinoma by Whole Exome Sequencing - Slides

P70. m6A reader IGF2BP1 High Protein Expression level Indicates a Poor Recovery for Lung Adenocarcinoma Patients - Slides

P70. Examples of Population Kinetics (PopKin) Assessments of Progression-Free (PFS) and Overall Survival (OS) - Slides

P70. Allelic Frequencies of Population Markers Correlate with KRAS G12C Prevalence: Considerations for Ancestries and Molecular Epidemiology - Slides

P70. Prevalence of KRAS and Concomitant Mutations in Advanced Lung Adenocarcinoma Patients - Slides

P70. NTRK Gene Fusion in Advanced Non Small Cell Lung Cancer at Pham Ngoc Thach Hospital - Viet Nam - Slides

P70. Impact of KRAS and Co-occurring Mutations on NSCLC Master Regulator Network as Determined by Computational Omics Biology Model. - Slides

P71. Targeting HSPA1A in ARID2-Deficient Lung Adenocarcinoma - Slides

P71. Molecular and Cellular Dynamics of Drug-Tolerant Persister (DTP) Cells During Osimertinib Therapy in EGFR Mutant Lung Adenocarcinoma - Slides

P71. A New Combination Therapy for FGFR1-Amplified Lung Cancer - Slides

P71. MiR-1243 Increases Radiosensitivity in EGFR-TKI Resistant Non-Small Cell Lung Cancer Cells - Slides

P71. Use of a Multiscale NSCLC Tumor Heterogeneity Model to Predict Tumor Growth Under Gefitinib - Slides

FP01. Prevalence, Treatment Patterns and Long-Term Clinical Outcomes of Patients with EGFR Positive Resected Stage IB-IIIA NSCLC - Slides

FP01. Prospective Observational Study of Activities of Daily Livings in Elderly Patients After Lung Cancer Surgery (JCOG1710A) - Slides

FP02. The Impact of Sex on Non-Small Cell Lung Cancer Survival in Canada - Slides

FP02. Factors Associated With Delayed Lung Cancer Diagnosis - Slides

FP04. Nivolumab 480 mg Every 4 Weeks as De Novo Second-line Treatment for Advanced Non-Small Cell Lung Cancer: CheckMate 907 - Slides

FP04. RATIONALE-307: Updated Biomarker Analysis of Phase 3 Study of Tislelizumab Plus Chemo vs Chemo Alone For 1L Advanced Sq-NSCLC - Slides

FP04. Clinical Benefit of First-Line Cemiplimab in Patients with Locally Advanced NSCLC: Subgroup Analysis from EMPOWER-Lung 1 - Slides

FP04. A Phase Ib/II Study of Imprime PGG and Pembrolizumab in Pretreated Patients With Advanced Stage Non-Small Cell Lung Cancer: BTCRC-LUN15-017 - Slides

FP05. A Biomarker-Directed, Multi-Center Phase II Study of Molecular Response Adaptive Immuno-Chemotherapy in Lung Cancer - Slides

FP05. Robust Discrimination of Lung Cancer via Microbial DNA Detection and Machine Learning Classification - Slides

FP07. Diagnostic Potential of Novel Mesothelioma-Specific MicroRNAs - Slides

FP07. DREAM3R: Durvalumab With Chemotherapy as First Line Treatment in Advanced Pleural Mesothelioma - A Phase 3 Randomised Trial - Slides

FP08. Lung Stereotactic Body Radiation Therapy for Treatment of Oligoprogressive and Oligorecurrent Metastatic Disease: A Multi-Center Analysis - Slides

FP08. Artificial Neural Network-Based Tumour Recurrence Prediction in Non-Small Cell Lung Cancer Patients Following Radical Radiotherapy - Slides

FP09. Mobocertinib in Platinum-Pretreated EGFR Exon 20 Insertion+ Metastatic NSCLC Patients With/Without Prior Anti-PD(L)-1 Therapy - Slides

FP09. Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes From EXCLAIM Extension Cohort - Slides

FP09. Phase II Randomized Trial to Evaluate Prednisone Taper With or Without Nintedanib for the Treatment of Radiation Pneumonitis - Slides

FP09. Impact of Brain Metastasis Status on Adverse Events (AEs) Requiring Dose Reduction Among Patients Receiving Lorlatinib - Slides

FP11. Sustaining and Accelerating Research in Rare Oncogene-Driven Lung Cancers: Lessons From The 2020 ROS1der Research Roundtable - Slides

FP12. PD-L1 Assessment in Cytology is Comparable to Histology in Predicting Treatment Response to Checkpoint Inhibitors in NSCLC - Slides

FP12. Pembrolizumab as a Monotherapy or in Combination With Platinum-Based Chemotherapy in NSCLC: Correlation With Blood Biomarkers - Slides

FP12. Obesity is Associated With Greater Overall Survival in Patients With Metastatic NSCLC Receiving First-Line Pembrolizumab - Slides

FP12. The Intrinsic Limitation and Clinical Impact of Mutant Allele-Specific Real-Time PCR-Based EGFR Mutation Assay in NSCLC - Slides

FP12. Clinico-demographic Factors, EGFR status and their association with Stage at Diagnosis in Lung Adenocarcinoma Patients - Slides

FP12. Lung Adenocarcinomas with ROS1 Rearrangement show Diffuse Strong ROS1 Immunohistochemical Staining - Slides

FP13. Assessment of the Fear of COVID-19 and Its Impact on Lung Cancer Screening Participation Among the Korean General Population - Slides

FP13. CHECK Lung Protocol: CT Lung Cancer Screening is Useful to Adjuvant Comorbid Diseases Diagnosis - Slides

FP14. Small Cell Lung Carcinoma’s Clinical Versatility Is a Manifestation of Its Shape-Shifting Cellular Programs - Slides

FP15. Randomized Single-Blind Comparative Study of Midazolam Plus Pethidine Combination and Midazolam During Bronchoscopy - Slides

FP16. Early Circulating-Tumor DNA EGFR Mutation Clearance in Plasma as a Predictor of Clinical Outcomes in The AURA3 Trial - Slides

FP16. A Nationwide Population-Based Mapping of Mutations and Gene Fusions in Lung Cancer Among Never-Smokers - Slides

P10. Adherence to Treatment Recommendations From Multidisciplinary Tumor Boards - Slides

P29. Evaluation of the Prognostic Marker of PD-L1 Expression After Combined Radiochemotherapy in Patients With NSCLC Stage III - Slides

P57. EGFR Mutational Status and PD-L1 in Early-Stage Brazilian Non-Small-Cell Lung Cancer - Slides

P70. Clinicopathological and Genetic Ancestry Impact of TP53 Mutations in Brazilian Lung Adenocarcinoma Patients - Slides